XBiotech Inc

XBITHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.95-0.02 (-1.02%)

2026-11-12 00:08 CET

Market cap

60.06 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-45.13 USD m

Free cash flow, TTM

-40.84 USD m

EPS diluted, TTM

-1.48

P/E

Compare

Price

XBIT against its 20, 50 and 200-day averages

2050200

43.3% under the 52-week high of 3.44 on 11 Nov 2025. 52-week low 1.80 on 28 Oct 2026. Last 15 sessions, 18.3% high to low

Volume 0.31× normal · the line is the 50-bar volume average

Profile

XBIT

52-week range, 9% of the way up

1.803.44

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Employees	85
IPO	Apr 15, 2015
Beta	0.73
ATR, 14d	0.10
Rel volume	0.31
Short float	1.64%
Insider own	36.87%
Inst own	6.43%

Snapshot

6 groups

Valuation

Index	-
Market Cap	59.45M
Enterprise Value	-50.08M
Income	-45.13M
Sales	0.00M
Book/sh	4.21
Cash/sh	3.59
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jul 15, 2021
Dividend Gr. 3/5Y	- -
Payout	-
Employees	85
IPO	Apr 15, 2015

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.46
P/C	0.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	33.15
Current Ratio	33.15
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

Earnings

EPS (ttm)	-1.48
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-11.39% -32.63%
Sales past 3/5Y	- -
EPS Y/Y TTM	-60.25%
Sales Y/Y TTM	-
EPS Q/Q	-283.16%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	36.87%
Insider Trans	3.39%
Inst Own	6.43%
Inst Trans	-0.80%
ROA	-28.90%
ROE	-29.94%
ROIC	-35.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.38%
SMA50	-6.93%
SMA200	-15.11%
Trades	-

Technical

Shs Outstand	30.49M
Shs Float	19.25M
Short Float	1.64%
Short Ratio	5.29
Short Interest	0.32M
52W High	3.44 -43.31%
52W Low	1.80 8.33%
Volatility	4.89% 6.24%
ATR (14)	0.10
RSI (14)	45.30
Beta	0.73
Rel Volume	0.31
Avg Volume	59.64K
Volume	18,559

Performance

Perf Week	0.00%
Perf Month	-9.72%
Perf Quarter	-16.31%
Perf Half Y	-22.00%
Perf YTD	-18.41%
Perf Year	-33.67%
Perf 3Y	-50.51%
Perf 5Y	-87.20%
Perf 10Y	-83.55%
Recom	3.00
Target Price	28.00
Prev Close	1.97
Price	1.95
Change %	-1.02%

Analyst ratings

latest 3 of 3

Date	Action	Analyst	Rating change	Target	Implied
Jun 14, 2019	Initiated	PPiper Jaffray	Overweight	$13	+566.7%
Apr 21, 2017	Downgrade	NNoble Financial	Buy → Hold	$13	+566.7%
Jun 28, 2016	Reiterated	NNoble Financial	Buy	$24 → $30	+1,438.5%

Date

Action

Analyst

Rating change

Target

Implied

Jun 14, 2019

Initiated

PPiper Jaffray

Overweight

$13

+566.7%

Apr 21, 2017

Downgrade

NNoble Financial

Buy → Hold

$13

+566.7%

Jun 28, 2016

Reiterated

NNoble Financial

Buy

$24 → $30

+1,438.5%

Peers

Mkt cap

Ticker	Company	Mkt cap
IVVD	Invivyd Inc	176.65M
ANAB	AnaptysBio Inc	1.46B
ABCL	AbCellera Biologics Inc	3.90B
VIR	Vir Biotechnology Inc	2.25B
IBIO	iBio Inc	50.16M
KNSA	Kiniksa Pharmaceuticals International Plc	7.52B
INO	Inovio Pharmaceuticals Inc	152.51M
CLDX	Celldex Therapeutics Inc	2.37B
ADMA	Adma Biologics Inc	2.93B
ATYR	Atyr Pharma Inc	16.60M

Ticker

Company

Mkt cap

IVVD

Invivyd Inc

176.65M

ANAB

AnaptysBio Inc

1.46B

ABCL

AbCellera Biologics Inc

3.90B

VIR

Vir Biotechnology Inc

2.25B

IBIO

iBio Inc

50.16M

KNSA

Kiniksa Pharmaceuticals International Plc

7.52B

INO

Inovio Pharmaceuticals Inc

152.51M

CLDX

Celldex Therapeutics Inc

2.37B

ADMA

Adma Biologics Inc

2.93B

ATYR

Atyr Pharma Inc

16.60M

Insider trading

1 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
SIMARD JOHN	Director	Oct 26 '26	Buy	1.93	368,524	711,251	4,191,690	Oct 28 02:37 PM

Insider

Relationship

Date

Transaction

Cost

Value

Total held

Form

SIMARD JOHN

Director

Oct 26 '26

Buy

1.93

368,524

711,251

4,191,690

Oct 28 02:37 PM

Held by

AUM

Ticker	Company	AUM
VXF	Vanguard Extended Market Index ETF	AUM: 30.47B
IWC	iShares Micro-Cap ETF	AUM: 1.22B
BSVO	EA Bridgeway Omni Small-Cap Value ETF	AUM: 2.44B
AVSC	Avantis U.S Small Cap Equity ETF	AUM: 3.23B

Ticker

Company

AUM

VXF

Vanguard Extended Market Index ETF

AUM: 30.47B

IWC

iShares Micro-Cap ETF

AUM: 1.22B

BSVO

EA Bridgeway Omni Small-Cap Value ETF

AUM: 2.44B

AVSC

Avantis U.S Small Cap Equity ETF

AUM: 3.23B

News

latest 14 of 200

Oct-23-26 09:17AMXBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers (GlobeNewswire)
Oct-19-26 09:00AMXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer (GlobeNewswire) -5.66%
Aug-13-26 11:57AMXBiotech: Q2 Earnings Snapshot (Associated Press) -5.28%
Jun-15-26 09:00AMXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis (GlobeNewswire)
May-14-26 02:50PMXBiotech: Q1 Earnings Snapshot (Associated Press)
Mar-13-26 04:16PMXBiotech: Q4 Earnings Snapshot (Associated Press Finance)
Nov-12-25 11:55AMXBiotech: Q3 Earnings Snapshot (Associated Press Finance) -5.78%
Aug-13-25 02:55PMXBiotech: Q2 Earnings Snapshot (Associated Press Finance) +5.72%
May-14-25 03:58PMXBiotech: Q1 Earnings Snapshot (Associated Press Finance)
Jan-14-25 04:37PMWolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating XBiotech for potential violations of securities laws (GlobeNewswire)
Dec-23-24 09:00AMXBiotech Pauses Rheumatology program (GlobeNewswire) -29.47%
Aug-12-24 02:45PMXBiotech: Q2 Earnings Snapshot (Associated Press Finance)
Jun-18-24 11:35AMXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer (GlobeNewswire) -13.49%
May-13-24 10:53AMXBIT Stock Earnings: XBiotech Reported Results for Q1 2024 (InvestorPlace)

Key figures

Revenue, TTM	0.00
Net income, TTM	-45.13
EPS diluted, TTM	-1.48
EBIT, TTM	-48.22
Free cash flow, TTM	-40.84
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	60.06
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
2019Q4	2020-02-26	-0.150	-	14.820	0.00	-	-

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

2019Q4

2020-02-26

-0.150

14.820

0.00

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2015FY	-1.220	-1.150	-1.220	-	-
2016FY	-1.630	-1.540	-1.630	0.00	0.00
2019FY	-0.620	-	14.435	0.00	-

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
EPS, annual	-0.95	-0.59	14.435	-0.364	-0.58	-1.081	-0.807	-1.265	-1.494	-1.4804
EPS, quarterly	-0.427	-0.165	-0.345	-0.357	-0.058	-0.197	-0.882	-0.181	-0.221
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Sales, annual	0	0	0	43.997	18.394	4.01	0	0	0	0
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Sales, quarterly	0	0	0	0	0	0	0	0	0
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Shares, annual	35.439	35.9	41.52	29.304	30.439	30.439	30.437	30.488	30.488	30.488
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	MRQ
Shares, quarterly	30.463	30.479	30.488	30.488	30.488	30.488	30.488	30.488	30.488
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Total Revenue	0.00	0.00	0.00	0.00	4.01	18.39	44.00	0.00	0.00
Cost of Goods Sold Incl. D&A	1.44	1.69	1.75	1.74	3.27	8.47	36.79	2.36	2.43
Gross Profit	-1.44	-1.69	-1.75	-1.74	0.74	9.93	7.21	-2.36	-2.43
Selling, General and Administrative Excl. Other	46.78	54.00	40.73	35.77	35.23	35.01	25.49	28.87	18.56
Research and Development	40.94	45.71	37.76	32.85	31.54	28.27	9.53	24.09	15.72
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-48.22	-55.69	-42.47	-37.51	-34.49	-25.08	-18.28	-31.23	-20.99
Interest Expense	-	0.09	0.81	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Net Income Before Taxes	-44.86	-45.30	-38.56	-24.31	-33.59	-25.46	-12.83	718.45	-21.14
Income Taxes	0.27	0.23	-0.03	0.24	-0.69	-8.04	-1.61	49.82	0.00
Consolidated Net Income	-45.13	-45.54	-38.53	-24.56	-32.90	-17.41	-11.22	668.63	-21.14
Net Income From Continuing Operations	-45.13	-45.54	-38.53	-24.56	-32.90	-17.41	-11.22	668.63	-21.14
Net Income	-45.13	-45.54	-38.53	-24.56	-32.90	-17.41	-11.22	668.63	-21.14
EPS (Recurring)	-1.48	-1.49	-1.26	-0.81	-1.08	-0.58	-0.36	14.44	-0.59
EPS (Basic, Before Extraordinaries)	-1.48	-1.49	-1.26	-0.81	-1.08	-0.58	-0.36	17.17	-0.59
EPS (Diluted)	-1.48	-1.49	-1.26	-0.81	-1.08	-0.58	-0.36	14.44	-0.59
EBITDA	-46.78	-54.00	-40.73	-35.77	-31.88	-22.43	-16.04	-28.87	-18.56
Non-Operating Income (Expense)	3.36	10.47	4.71	13.20	0.90	-0.38	5.45	749.69	-0.14
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	0.42	2.86	1.38	2.58	4.00	3.26	9.18	2.45	1.66
Price To Earnings Ratio	-	-	-	-	-	-	-	1.15	-
Price To Sales Ratio	-	-	-	-	26.64	18.18	10.96	-	-
Gross Margin	-	-	-	-	18.58	53.96	16.39	-	-
Operating Margin	-	-	-	-	-860.10	-136.36	-41.54	-	-
Net Margin	-	-	-	-	-820.45	-94.67	-25.50	-	-
Shares Outstanding	30.49	30.49	30.49	30.44	30.44	30.44	29.30	41.52	35.90
Market Capitalization	60.06	60.06	120.41	121.75	106.84	338.34	404.72	677.79	159.48

Income statement, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.30	0.33	0.38	0.43	0.44	0.44	0.44	0.44
Gross Profit	-0.30	-0.33	-0.38	-0.43	-0.44	-0.44	-0.44	-0.44
Selling, General and Administrative Excl. Other	5.84	5.94	29.38	5.62	5.90	13.11	8.31	7.46
Research and Development	5.30	5.21	25.36	5.08	5.34	11.62	7.82	7.13
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-6.15	-6.27	-29.75	-6.05	-6.34	-13.55	-8.75	-7.90
Interest Expense	0.00	0.00	-	0.00	-	0.09	0.20	0.20
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	-6.68	-5.46	-26.82	-5.91	-1.73	-10.86	-10.55	-5.01
Income Taxes	0.05	0.05	0.08	0.10	0.03	0.03	-0.04	0.01
Consolidated Net Income	-6.73	-5.50	-26.89	-6.01	-1.76	-10.88	-10.51	-5.01
Net Income From Continuing Operations	-6.73	-5.50	-26.89	-6.01	-1.76	-10.88	-10.51	-5.01
Net Income	-6.73	-5.50	-26.89	-6.01	-1.76	-10.88	-10.51	-5.01
EPS (Recurring)	-0.22	-0.18	-0.88	-0.20	-0.06	-0.36	-0.34	-0.16
EPS (Basic, Before Extraordinaries)	-0.22	-0.18	-0.88	-0.20	-0.06	-0.36	-0.34	-0.16
EPS (Diluted)	-0.22	-0.18	-0.88	-0.20	-0.06	-0.36	-0.34	-0.16
EBITDA	-5.84	-5.94	-29.38	-5.62	-5.90	-13.11	-8.31	-7.46
Non-Operating Income (Expense)	-0.54	0.82	2.94	0.14	4.61	2.78	-1.60	3.10
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	0.14	0.14	0.13	0.02	0.08	2.63	0.50	0.29
Shares Outstanding	30.49	30.49	30.49	30.49	30.49	30.49	30.49	30.48
Market Capitalization	60.06	71.65	72.87	81.10	90.55	98.78	120.41	235.48

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY	2017FY
Cash & Short Term Investments	125.55	172.68	200.02	217.48	236.98	237.37	714.59	15.82	31.77
Short Term Receivables	0.36	0.86	0.94	1.76	8.95	85.75	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.04	1.03	0.76	0.60	0.93	0.58	1.67	1.19	1.56
Total Current Assets	126.95	174.57	201.72	219.84	246.87	323.70	716.26	17.02	33.33
Net Property, Plant & Equipment	23.13	24.53	24.90	26.26	28.31	27.34	25.17	27.33	29.64
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00	75.00	0.00	0.00
Intangible Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.18	-	0.63	1.66	1.09	1.28	0.89	-	-
Other Assets	0.00	0.00	0.00	0.00	0.00	2.18	0.00	0.00	0.00
Total Assets	150.26	199.09	227.24	247.76	276.27	354.50	817.32	44.34	62.97
Short Term Debt Incl. Current Port. of LT Debt	0.00	10.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	1.53	2.22	2.52	2.41	2.07	2.49	2.15	1.65	1.73
Income Tax Payable	0.08	0.00	0.08	0.06	0.01	0.14	-	-	-
Other Current Liabilities	6.32	2.63	3.50	1.60	1.37	1.35	58.04	1.29	1.06
Total Current Liabilities	7.93	15.11	6.10	4.07	3.45	3.98	60.19	2.94	2.79
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	0.18	-	0.63	1.72	1.96	0.75	0.45	-	-
Other Liabilities	1.80	1.72	1.67	1.58	1.47	1.12	1.06	0.00	0.02
Total Liabilities	9.91	16.82	8.40	7.36	6.88	5.86	61.69	2.95	2.81
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	140.35	182.27	218.85	240.40	269.38	348.64	755.63	41.40	60.16
Total Shareholders Equity	140.35	182.27	218.85	240.40	269.38	348.64	755.63	41.40	60.16
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	140.35	182.27	218.85	240.40	269.38	348.64	755.63	41.40	60.16
Total Liabilities & Stockholders Equity	150.26	199.09	227.24	247.76	276.27	354.50	817.32	44.34	62.97
Book Value Per Share	4.60	5.98	7.19	7.90	8.85	11.90	18.20	1.15	1.70
Tangible Book Value Per Share	4.60	5.98	7.19	7.90	8.85	11.90	18.20	1.15	1.70
Full-Time Employees	85	92	82	85	97	91	60	53	51
Price to Book Ratio	0.47	0.63	0.55	0.44	1.26	1.16	0.91	3.89	1.84
Return on Assets	-26.07	-18.08	-10.34	-12.56	-5.52	-1.92	155.19	-39.39	-50.99
Return on Equity	-28.23	-19.21	-10.69	-12.91	-5.64	-2.03	167.78	-41.63	-55.61
Return on Invested Capital	-32.45	-21.14	-11.22	-13.69	-6.46	-3.22	88.49	-51.06	-55.10
Quick Ratio	16.01	11.56	33.07	54.07	71.49	81.25	11.90	5.78	11.94
Current Ratio	16.01	11.56	33.07	54.07	71.49	81.25	11.90	5.78	11.94

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Net Income	-45.13	-45.54	-38.53	-24.56	-32.90	-17.41	-11.22	668.63	-21.14
Depreciation	1.44	1.69	1.75	1.74	2.61	2.65	2.24	2.36	2.43
Other Funds (Non Cash)	3.11	0.29	7.28	1.37	7.86	4.46	12.58	-746.64	1.66
Funds from Operations	-40.58	-43.56	-29.50	-21.44	-23.24	-10.30	3.51	-76.10	-17.05
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-0.11	3.64	-1.46	2.72	8.41	79.75	-68.66	57.83	0.51
Income Taxes Payable	-0.02	0.08	-0.02	0.12	0.15	0.21	0.07	49.36	-
Cash from Operating Activities	-40.70	-39.92	-30.96	-18.73	-14.82	69.44	-65.15	-18.27	-16.54
Capital Expenditures	-0.14	-0.29	-1.30	-0.36	-0.58	-3.52	-3.73	-0.20	-0.12
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	675.00	-
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	-63.31	0.00	0.00	0.00	0.00
Other Sources	0.01	0.00	0.00	61.86	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-0.14	-0.29	-1.30	61.50	-63.89	-3.52	-3.73	674.80	-0.12
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	-75.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	0.20	0.01	0.00	8.00	-409.72	42.10	0.20
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	0.20	0.01	0.00	8.00	-409.72	42.10	0.20
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.36	0.00
Issuance or Reduction of Debt, Net	0.00	-10.25	10.25	0.00	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	0.00	-10.25	10.45	-0.01	0.00	-67.01	-409.72	42.10	0.20
Exchange Rate Effect	-2.58	3.33	-5.53	-0.05	-0.96	0.70	1.37	0.15	0.51
Net Change in Cash	-43.41	-47.13	-27.35	42.72	-79.68	-0.38	-477.23	698.77	-15.95
Free Cash Flow	-40.84	-40.21	-32.27	-19.09	-15.41	65.92	-68.88	-18.47	-16.66
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Taxes & Investment Tax Credit	-	0.01	0.00	0.00	-0.81	0.00	-0.09	-0.44	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1
Cash & Short Term Investments	109.53	115.46	125.55	147.37	152.94	155.90
Short Term Receivables	0.29	0.30	0.36	0.53	0.64	0.64
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.34	1.29	1.04	1.06	1.31	1.15
Total Current Assets	111.16	117.05	126.95	148.95	154.89	157.69
Net Property, Plant & Equipment	22.49	22.79	23.13	23.47	23.79	24.18
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	-	-	0.18	-	-	-
Other Assets	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	133.65	139.84	150.26	172.42	178.68	181.86
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	1.10	0.86	1.53	1.04	1.43	1.10
Income Tax Payable	0.00	0.11	0.08	0.10	0.02	0.01
Other Current Liabilities	2.25	2.04	6.32	2.42	2.41	4.30
Total Current Liabilities	3.35	3.00	7.93	3.56	3.86	5.41
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	0.01	0.01	0.18	-	-	-
Other Liabilities	1.83	1.81	1.80	1.78	1.76	1.74
Total Liabilities	5.19	4.82	9.91	5.34	5.62	7.15
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	128.46	135.02	140.35	167.08	173.06	174.71
Total Shareholders Equity	128.46	135.02	140.35	167.08	173.06	174.71
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	128.46	135.02	140.35	167.08	173.06	174.71
Total Liabilities & Stockholders Equity	133.65	139.84	150.26	172.42	178.68	181.86
Book Value Per Share	4.21	4.43	4.60	5.48	5.68	5.73
Tangible Book Value Per Share	4.21	4.43	4.60	5.48	5.68	5.73
Full-Time Employees	87	87	85	-	92	90
Price to Book Ratio	0.47	0.51	0.44	0.47	0.52	0.54
Return on Assets	-28.90	-24.97	-26.07	-15.25	-14.29	-19.24
Return on Equity	-29.94	-25.93	-28.23	-16.23	-15.23	-20.53
Return on Invested Capital	-5.24	-4.08	-19.16	-3.60	-1.01	-6.23
Quick Ratio	33.15	39.03	16.01	41.78	40.16	29.15
Current Ratio	33.15	39.03	16.01	41.78	40.16	29.15

Cash flow, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1
Net Income	-6.73	-5.50	-26.89	-6.01	-1.76	-10.88
Depreciation	0.30	0.33	0.38	0.43	0.44	0.44
Other Funds (Non Cash)	1.58	1.30	-1.01	1.23	-2.97	3.04
Funds from Operations	-4.84	-3.87	-27.52	-4.36	-4.29	-7.40
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	0.33	-5.10	4.57	0.10	-1.70	0.68
Income Taxes Payable	-0.09	0.05	-0.08	0.10	0.03	0.03
Cash from Operating Activities	-4.51	-8.97	-22.95	-4.26	-5.99	-6.72
Capital Expenditures	0.00	0.00	-0.03	-0.11	-0.05	-0.09
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	-0.00	0.01	0.00	0.00	0.00	0.00
Cash from Investing Activities	-0.00	0.01	-0.03	-0.11	-0.05	-0.09
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	0.00	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00	0.00	-10.25
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	0.00	0.00	0.00	0.00	0.00	-10.25
Exchange Rate Effect	-1.41	-1.13	1.17	-1.20	3.08	0.28
Net Change in Cash	-5.93	-10.09	-21.82	-5.57	-2.96	-16.78
Free Cash Flow	-4.51	-8.97	-22.99	-4.37	-6.04	-6.81

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	1.64%	0.3M	19.3M	55.44K
2026-10-15	1.56%	0.3M	19.3M	42.41K
2026-09-30	1.42%	0.3M	23.1M	40.68K
2026-09-15	1.50%	0.3M	23.1M	40.69K
2026-08-31	1.49%	0.3M	23.1M	33.88K
2026-08-14	1.44%	0.3M	23.1M	33.65K
2026-07-31	1.41%	0.3M	23.1M	33.14K
2026-07-15	1.22%	0.3M	23.1M	30.29K
2026-06-30	1.19%	0.3M	23.1M	27.66K
2026-06-15	0.93%	0.2M	23.1M	33.65K
2026-05-29	0.79%	0.2M	23.1M	32.85K
2026-05-15	0.95%	0.2M	19.3M	32.92K
2026-04-30	0.90%	0.2M	19.3M	37.38K
2026-04-15	0.77%	0.1M	19.3M	38.70K
2026-03-31	0.75%	0.1M	19.3M	43.86K
2026-03-13	0.62%	0.1M	19.3M	38.95K
2026-02-27	0.56%	0.1M	19.3M	47.70K
2026-02-13	0.57%	0.1M	19.3M	54.36K
2026-01-30	0.59%	0.1M	19.3M	97.87K
2026-01-15	0.53%	0.1M	19.3M	100.51K

Option chain

expiry 2026-11-20

Type	Strike	Bid	Ask	Last	IV	Open int	Delta	Theta	Vega
call	2.50	0.00	2.85	0.10	10.083	12.00	0.735	-0.057	0.001
call	5.00	0.00	0.20	0.15	4.628	778	0.176	-0.021	0.001
call	7.50	0.00	2.85	0.00	7.041	0.00	0.248	-0.038	0.001
put	2.50	0.00	4.90	0.00	2.196	0.00	-0.265	-0.057	0.001
put	5.00	1.75	5.50	0.00	0.000	0.00	-0.725	-0.033	0.001
put	7.50	4.20	8.00	0.00	0.000	0.00	-0.752	-0.037	0.001

Latest SEC filings

Filed	Form	Description	Period	Link
2026-10-28	4	Statement of changes in beneficial ownership of securities	2026-10-26	SEC
2026-10-28	3	Initial statement of beneficial ownership of securities	2026-10-23	SEC
2026-10-28	4	Statement of changes in beneficial ownership of securities	2026-10-26	SEC
2026-10-26	8-K	Current report	2026-10-23	SEC
2026-10-02	ARS	Annual report to security holders.	2026-10-02	SEC
2026-10-02	DEF 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2026-11-24	SEC
2026-08-13	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-06-30	SEC
2026-05-14	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-03-31	SEC
2026-04-29	10-K/A		2025-12-31	SEC
2026-03-13	10-K	Annual report pursuant to Section 13 or 15(d)	2025-12-31	SEC
2026-03-11	S-8	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans		SEC
2026-01-23	SCHEDULE 13G/A			SEC
2026-01-23	SCHEDULE 13G/A			SEC
2025-12-09	8-K	Current report	2025-12-05	SEC
2025-11-12	4	Statement of changes in beneficial ownership of securities	2025-10-01	SEC
2025-11-12	4	Statement of changes in beneficial ownership of securities	2025-10-01	SEC
2025-11-12	4	Statement of changes in beneficial ownership of securities	2025-10-01	SEC
2025-11-12	4	Statement of changes in beneficial ownership of securities	2025-10-01	SEC
2025-11-12	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2025-09-30	SEC
2025-10-15	8-K/A		2025-06-24	SEC
2025-10-03	8-K	Current report	2025-10-01	SEC
2025-09-30	3	Initial statement of beneficial ownership of securities	2025-08-29	SEC
2025-09-30	3	Initial statement of beneficial ownership of securities	2025-08-29	SEC
2025-09-29	3	Initial statement of beneficial ownership of securities	2025-08-29	SEC
2025-09-16	3	Initial statement of beneficial ownership of securities	2025-08-29	SEC
2025-09-02	8-K	Current report	2025-08-29	SEC
2025-08-13	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2025-06-30	SEC
2025-07-07	ARS	Annual report to security holders.	2024-12-31	SEC
2025-07-07	DEF 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2025-08-29	SEC
2025-06-24	8-K	Current report	2025-06-24	SEC

Insider activity by month

Month	Bought	Buys
2026-11	0	0
2026-10	711.25K	1
2026-09	0	0
2026-08	0	0
2026-07	0	0
2026-06	0	0
2026-05	0	0
2026-04	0	0
2026-03	0	0
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Institutional holders

Manager	% owned
BlackRock, Inc.	1.05%
GEODE CAPITAL MANAGEMENT, LLC	0.70%
VANGUARD CAPITAL MANAGEMENT LLC	0.66%
RBF Capital, LLC	0.65%
MORGAN STANLEY	0.49%
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.32%
VANGUARD FIDUCIARY TRUST CO	0.30%
MILLENNIUM MANAGEMENT LLC	0.26%
STATE STREET CORP	0.24%
NORTHERN TRUST CORP	0.22%

Funds

Fund	% owned
VANGUARD EXTENDED MARKET INDEX FUND	0.66%
Fidelity Extended Market Index Fund	0.31%
iShares Micro-Cap ETF	0.26%
EA Bridgeway Omni Small-Cap Value ETF	0.20%
Ultra-Small Company Fund	0.13%
Fidelity Total Market Index Fund	0.12%
Fidelity Series Total Market Index Fund	0.09%
Fidelity Nasdaq Composite Index Fund	0.05%
Avantis U.S. Small Cap Equity ETF	0.04%
1290 VT Micro Cap Portfolio	0.02%

Dividends

per share

Ex date

Ordinary

Special

2021-07-15

0.0000

2.5000

Period	Amount	Yield	Payout	Kind
2021FY	2.4700	22.19%	-%	paid
2022FY	0.0000	0.00%	-%	paid
2023FY	0.0000	0.00%	-%	paid
2024FY	0.0000	0.00%	-%	paid
2025FY	0.0000	0.00%	-%	paid

OakChart. XBIT. Cached 15 minutes.